New hope for kids with hepatitis b: drug combo aims for cure
NCT ID NCT07345611
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding pegylated interferon to entecavir helps young children (ages 3-6) with chronic hepatitis B achieve a functional cure, meaning the virus becomes undetectable. Sixty children will receive either entecavir alone or entecavir followed by the combination. The goal is to see if the combo leads to better long-term control of the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- entecavir and pegylated interferon α-2b
- What this could lead to
- If successful, this could offer a way to achieve functional cure in young children with chronic hepatitis B, potentially reducing long-term liver damage.
- What could go wrong
- This is a small, early-phase trial with only 60 children, and the combination therapy may cause more side effects. Functional cure is not guaranteed, and long-term benefits remain uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a new formula save more children from severe malnutrition?
- Can a new sedative combo make Children's gastroscopy safer?
- Could a buzzing device make childhood shots painless?
- Can a new injection tame chronic hepatitis b?